Positron emission imaging of head and neck cancer, including thyroid carcinoma.

Most positron emission tomography (PET) imaging studies in head and neck cancer are performed using the radiotracer 18-fluorodeoxyglucose ((18)FDG). PET with FDG has become a standard clinical imaging modality in patients with head and neck cancer. It contributes valuable information in localizing a primary tumor in patients with neck nodal metastases from an unknown primary, in the staging of primary head and neck cancer, and in the detection of recurrent disease. In addition, FDG-PET provides independent prognostic information in patients with newly diagnosed and recurrent head and neck cancer. PET/CT improves lesion localization and accuracy of FDG-PET and is strongly recommended in patients with head and neck cancer. After thyroidectomy, FDG-PET has proven useful in patients with clinical or serological evidence of recurrent or metastatic thyroid carcinoma but negative whole body iodine scan. PET shows metastatic disease in up to 90% of these patients, thereby providing a rational basis for further studies and therapy. In patients with medullary thyroid cancer with elevated calcitonin levels following thyroidectomy, FDG-PET has a sensitivity of 70-75% for localizing metastatic disease. Occasionally incidental intense FDG uptake is observed in the thyroid gland on whole body PET studies performed for other indications. Although diffuse FDG uptake usually indicates thyroiditis, focal uptake has been related to thyroid cancer in 25-50% of cases and should therefore be evaluated further if a proven malignancy would cause a change in patient management.

[1]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[2]  Mithat Gonen,et al.  Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. , 2004, Radiology.

[3]  T. Whiteside,et al.  Detection of recurrent oral squamous cell carcinoma by [18F]‐2‐fluorodeoxyglucose‐positron emission tomography , 2003, Cancer.

[4]  J. Eary,et al.  Staging of head and neck squamous cell cancer with extended-field FDG-PET. , 2003, Archives of otolaryngology--head & neck surgery.

[5]  R. Wahl,et al.  Direct Comparison of 18F-FDG PET and PET/CT in Patients with Colorectal Carcinoma , 2003 .

[6]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[7]  Seung-Yong Jeong,et al.  Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[8]  C. Tempany,et al.  Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. , 2003, Radiology.

[9]  V. Lowe,et al.  18F-FDG PET of patients with Hürthle cell carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  A. Kuten,et al.  Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  K. Onizawa,et al.  Evaluation of 67Ga citrate and 99mTc bone scintigraphy at initial examination for primary oral squamous cell carcinoma , 2003 .

[12]  M. Pan,et al.  18‐Fluoro‐2‐deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging , 2003, Cancer.

[13]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[14]  A. Bockisch,et al.  Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report , 2003, European Radiology.

[15]  Stephanie L. Lee,et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[16]  L. Peters,et al.  The usefulness of fluorine 18–labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor , 2003, Head & neck.

[17]  M. Merino,et al.  Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. , 2003, The Journal of clinical endocrinology and metabolism.

[18]  N. Sadato,et al.  Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Mithat Gonen,et al.  Diagnostic and Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomography for Recurrent Head and Neck Squamous Cell Carcinoma , 2002 .

[20]  S. Berlangieri,et al.  Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Histopathologic Correlation in the Initial Staging of Head and Neck Cancer , 2002 .

[21]  A. Vissink,et al.  Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  S. Larson,et al.  Positron emission tomography in thyroid cancer management. , 2002, Seminars in roentgenology.

[23]  G. Reischl,et al.  Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Mohamed Allaoua,et al.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Petrich,et al.  Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  M N Maisey,et al.  FDG–PET. A possible prognostic factor in head and neck cancer , 2002, British Journal of Cancer.

[27]  Elisabeth Kjellén,et al.  FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma , 2002, Head & neck.

[28]  F. Mottaghy,et al.  Implication of 2-18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hürthle cell thyroid cancer. , 2002, Thyroid : official journal of the American Thyroid Association.

[29]  K. Ang,et al.  Cervical lymph node metastases from occult squamous cell carcinoma , 2002, Current treatment options in oncology.

[30]  M. Cohen,et al.  Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. , 2001, Surgery.

[31]  R. Görges,et al.  Preoperative Diagnostic Value of [18F] Fluorodeoxyglucose Positron Emission Tomography in Patients With Radioiodine-Negative Recurrent Well-Differentiated Thyroid Carcinoma , 2001, Annals of surgery.

[32]  R. D'Agostino,et al.  Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer , 2001, Head & neck.

[33]  P. V. van Rijk,et al.  F‐18‐fluoro‐deoxy‐glucose positron‐emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/ pharyngeal cancer , 2001, Head & neck.

[34]  P. Merlet,et al.  Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  J. Bredow,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study , 2001, European Journal of Nuclear Medicine.

[36]  W. Mann,et al.  [Fluorine-18]Fluorodeoxyglucose Positron Emission Tomography, DNA Ploidy and Growth Fraction in Squamous-Cell Carcinomas of the Head and Neck , 2001, ORL.

[37]  K. Ang,et al.  Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple? , 2001, International journal of radiation oncology, biology, physics.

[38]  P. Mikosch,et al.  Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods , 2001, European Journal of Nuclear Medicine.

[39]  S. Larson,et al.  Incidental Focal Thyroid Uptake on FDG Positron Emission Tomographic Scans May Represent a Second Primary Tumor , 2001, Clinical nuclear medicine.

[40]  A. Alavi,et al.  Evaluation of Recurrent Squamous Cell Carcinoma of the Head and Neck with FDG Positron Emission Tomography , 2001, Clinical nuclear medicine.

[41]  P. Chieng,et al.  Comparison of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography and Computed Tomography in Detection of Cervical Lymph Node Metastases of Nasopharyngeal Carcinoma , 2000, The Annals of otology, rhinology, and laryngology.

[42]  R. Baum,et al.  Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. , 2000, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[43]  R. Tiling,et al.  Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  B. Nowak,et al.  Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. , 2000, Archives of otolaryngology--head & neck surgery.

[45]  M. Remacle,et al.  Positron Emission Tomography With Fluorodeoxyglucose for Suspected Head and Neck Tumor Recurrence in the Symptomatic Patient , 2000, The Laryngoscope.

[46]  U. Pietrzyk,et al.  2[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography is a Sensitive Tool for the Detection of Occult Primary Cancer (Carcinoma of Unknown Primary Syndrome) with Head and Neck Lymph Node Manifestation , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[47]  L. Friberg,et al.  Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. , 2000, European journal of cancer.

[48]  J A Werner,et al.  FDG PET detection of unknown primary tumors. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  A. Bockisch,et al.  The value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with medullary thyroid cancer , 2000, European Journal of Nuclear Medicine.

[50]  W. Goodwin.  Salvage Surgery for Patients With Recurrent Squamous Cell Carcinoma of the Upper Aerodigestive Tract: When Do the Ends Justify the Means? , 2000, The Laryngoscope.

[51]  S. Larson,et al.  Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[52]  M. Brekel.  Lymph node metastases: CT and MRI. , 2000 .

[53]  B C Stack,et al.  Surveillance for recurrent head and neck cancer using positron emission tomography. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  P. V. van Rijk,et al.  Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography. , 2000, Annals of surgery.

[55]  M. Schwaiger,et al.  Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. , 1999, Archives of otolaryngology--head & neck surgery.

[56]  K. Olsen.  Head and Neck Cancer: A Multidisciplinary Approach , 1999 .

[57]  O. Schober,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.

[58]  P. V. van Rijk,et al.  18F‐fluorodeoxyglucose dual‐head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer , 1999, Cancer.

[59]  D. Soutar,et al.  Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection , 1999, Head & neck.

[60]  N. Sadato,et al.  FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  P. V. van Rijk,et al.  The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography. , 1999, Oral oncology.

[62]  K. Greven,et al.  Occult primary tumors of the head and neck , 1999, Cancer.

[63]  P. V. van Rijk,et al.  The detection of local recurrent head and neck cancer with fluroine-18 fluorodeoxyglucose dual-head positron emission tomography , 1999, European Journal of Nuclear Medicine.

[64]  M. Hanasono,et al.  Uses and limitations of fdg positron emission tomography in patients with head and neck cancer , 1999, The Laryngoscope.

[65]  D. Lee,et al.  Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[66]  A. Alavi,et al.  Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2‐18f‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography , 1999, The Laryngoscope.

[67]  L. Mcclymont,et al.  Radiological staging of the chest and abdomen in head and neck squamous cell carcinoma – are computed tomography and ultrasound necessary? , 1999, The Journal of Laryngology & Otology.

[68]  S. Stringer,et al.  SQUAMOUS CELL CARCINOMA METASTATIC TO CERVICAL LYMPH NODES FROM AN UNKNOWN HEAD AND NECK PRIMARY SITE , 1998 .

[69]  G. Hör,et al.  Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer , 1998, European Journal of Nuclear Medicine.

[70]  M. Singer,et al.  Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. , 1998, AJNR. American journal of neuroradiology.

[71]  S. Yasuda,et al.  Chronic thyroiditis: diffuse uptake of FDG at PET. , 1998, Radiology.

[72]  K. Greven,et al.  Laryngeal Radionecrosis versus Recurrent Cancer: A Clinical Approach , 1998, The Annals of otology, rhinology, and laryngology.

[73]  B J McNeil,et al.  Comparison of CT and MR Imaging in Staging of Neck , 2005 .

[74]  O. Schober,et al.  Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans , 1998, Langenbeck's Archives of Surgery.

[75]  J. Roodenburg,et al.  Detection of unknown occult primary tumors using positron emission tomography , 1998, Cancer.

[76]  V. Lowe,et al.  Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F‐18]fluorodeoxyglucose positron emission tomography , 1997, Head & neck.

[77]  M. Dietlein,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer , 1997, European Journal of Nuclear Medicine.

[78]  I. Mcdougall.  131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? , 1997, Thyroid : official journal of the American Thyroid Association.

[79]  J. Roodenburg,et al.  Detection of unknown primary head and neck tumors by positron emission tomography. , 1997, International journal of oral and maxillofacial surgery.

[80]  W. Mcguirt.  Laryngeal radionecrosis versus recurrent cancer. , 1997, Otolaryngologic clinics of North America.

[81]  J. Hanke,et al.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[82]  K S Pentlow,et al.  Quantitative imaging of iodine-124 with PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[83]  R. Wahl,et al.  Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. , 1996, Radiology.

[84]  H. Biersack,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer , 1996, European Journal of Nuclear Medicine.

[85]  H. Minn,et al.  Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. , 1995, Radiology.

[86]  J. Hanke,et al.  [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. , 1995, Nuklearmedizin. Nuclear medicine.

[87]  K. Ain,et al.  Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. , 1995, The Journal of clinical endocrinology and metabolism.

[88]  K. Geisinger,et al.  A comparative diagnostic study of head and neck nodal metastases using positron emission tomography , 1995, The Laryngoscope.

[89]  K. Geisinger,et al.  Positron Emission Tomography in the Evaluation of Laryngeal Carcinoma , 1995, The Annals of otology, rhinology, and laryngology.

[90]  L. Strauss,et al.  Chemotherapeutic management of head and neck malignancies with positron emission tomography. , 1995, Archives of otolaryngology--head & neck surgery.

[91]  R L Wahl,et al.  Squamous Cell Carcinoma of the Head and Neck , 2006 .

[92]  E. Touboul,et al.  Synchronous and metachronous head and neck carcinomas , 1994, Cancer.

[93]  K. Geisinger,et al.  Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation , 1994, Cancer.

[94]  R. Lufkin,et al.  Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers , 1994 .

[95]  J. Field,et al.  The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary sites. , 1994, Clinical otolaryngology and allied sciences.

[96]  P. Zbären,et al.  [Cervical lymph node metastases]. , 1993, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.

[97]  R. Lufkin,et al.  Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. , 1993, Radiology.

[98]  J. Shah,et al.  Cervical lymph node metastasis. , 1993, Current problems in surgery.

[99]  G van Kaick,et al.  Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[100]  J Valk,et al.  Cervical lymph node metastasis: assessment of radiologic criteria. , 1990, Radiology.

[101]  I. Hay.  Papillary thyroid carcinoma. , 1990, Endocrinology and metabolism clinics of North America.

[102]  H. Minn,et al.  Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[103]  J. Field,et al.  Effects of thyrotropin, carbachol, and protein kinase-C stimulators on glucose transport and glucose oxidation by primary cultures of dog thyroid cells. , 1988, Endocrinology.

[104]  A. Pinchera,et al.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[105]  S. Filetti,et al.  Thyrotropin stimulates glucose transport in cultured rat thyroid cells. , 1987, Endocrinology.

[106]  C. O'brien,et al.  Neck dissection with and without radiotherapy: prognostic factors, patterns of recurrence, and survival. , 1986, American journal of surgery.

[107]  V. Schramm,et al.  Extracapsular spread of carcinoma in cervical lymph nodes impact upon survival in patients with carcinoma of the supraglottic larynx , 1985, Cancer.

[108]  V. Schramm,et al.  Cervical lymph node metastases. Incidence and implications of extracapsular carcinoma. , 1985, Archives of otolaryngology.

[109]  V. Schramm,et al.  The extracapsular spread of tumors in cervical node metastasis. , 1981, Archives of otolaryngology.

[110]  H. Maxon,et al.  The Role of Nuclear Medicine in the Treatment of Hyperthyroidism and Well‐Differentiated Thyroid Adenocarcinoma , 1981, Clinical nuclear medicine.

[111]  E. Mazzaferri,et al.  Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. , 1981, The American journal of medicine.

[112]  F. K. Bauer,et al.  Radioactive iodine (I131) in the postoperative treatment of thyroid cancer , 1960 .

[113]  G. V. von Schulthess,et al.  Positron emission tomography in the early follow-up of advanced head and neck cancer. , 2004, Archives of otolaryngology--head & neck surgery.

[114]  H. Joensuu,et al.  18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy , 2004, European Journal of Nuclear Medicine.

[115]  K. Onizawa,et al.  Evaluation of 67 Ga citrate and 99m Tc bone scintigraphy at initial examination for primary oral squamous cell carcinoma. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[116]  R. Wahl,et al.  Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[117]  N. Sadato,et al.  Prospective Comparison of 18 F-FDG PET with Conventional Imaging Modalities ( MRI , CT , and 67 Ga Scintigraphy ) in Assessment of Combined Intraarterial Chemotherapy and Radiotherapy for Head and Neck Carcinoma , 2003 .

[118]  S. Berlangieri,et al.  Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. , 2002, Annals of surgery.

[119]  S. Larson,et al.  Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  T. Petrich,et al.  Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. , 2002, European journal of nuclear medicine and molecular imaging.

[121]  N. Sadato,et al.  FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[122]  K. Eichler,et al.  Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. , 2002, Radiology.

[123]  L. Hann,et al.  Advances in the detection of residual thyroid carcinoma. , 2001, Advances in internal medicine.

[124]  E. Nitzsche,et al.  18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels , 2001, European Journal of Nuclear Medicine.

[125]  R. Buchert,et al.  Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[126]  A. Santin.  Lymph node metastases , 2000, Cancer.

[127]  M. Singer,et al.  Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. , 1999, Radiology.

[128]  G. V. von Schulthess,et al.  FDG PET-negative liver metastases of a malignant melanoma and FDG PET-positive Hurthle cell tumor of the thyroid , 1999, European Radiology.

[129]  S. Larson,et al.  [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.

[130]  K. Geisinger,et al.  Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. , 1994, International journal of radiation oncology, biology, physics.

[131]  G. Snow,et al.  Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor , 1994, Cancer.

[132]  P. Boracchi,et al.  Analysis of prognostic factors and proposal of a new classification for nasopharyngeal cancer , 1990, Head & neck.

[133]  R. Nordyke,et al.  Radioactive iodine (I 131) in the postoperative treatment of thyroid cancer. , 1960, Cancer.